BMED iShares Health Innovation Active ETF
Quote as of Oct 09, 2026 18:17 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 33.65 | Day Range | 33.65 – 33.65 |
| 52-Week Range | 27.25 – 34.98 | Volume | 1.60K |
| Avg Volume | 1.99K | AUM | $13.7M (Oct 12, 2026) |
| Expense Ratio | 0.77% | Yield (TTM) | 0.24% |
| NAV | 34.34 | Premium/Discount | -2.01% indicative |
| Inception | Sep 29, 2020 | Holdings | 56 |
| Issuer | iShares | Exchange | AMEX |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 09290C400 | ISIN | US09290C4006 |
| Management | Not stated in source data | ||
About this ETF
BMED focuses on total return by investing in the broad health sciences group of industries from R&D to production and distribution of medical supplies in different fields, including dental, optical or pharmaceuticals. It also involves healthcare providers including health facilities and hospitals or those providing related administrative, management or financial support. The fund reaches into non-human health (e.g., survival of plants and animals) such as firms that increase crop yields, taste, nutritional content or improve pet health. BMED will include firms with varying market-cap with bias to small- and mid-caps that may include foreign non-USD-denominated securities. The fund may also hold REITs that own hospitals and IPOs. During temporary defensive periods, the fund may invest up to 100% of assets in liquid, short-term investments and can enter in credit default swaps for risk management. Prior to Oct. 10, 2024, the fund used Blackrock for branding purposes instead of iShares.
Description from the fund data provider · profile as of Oct 12, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +3.93% | +11.53% | +19.03% | +13.26% | +23.57% | +14.92% | +3.44% | — | +5.23% |
| Total return | +3.93% | +11.53% | +19.36% | +13.56% | +23.93% | +15.04% | +3.50% | — | +5.28% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.77% | Annual cost of a $10,000 investment | $77.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 59 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | DANAHER | DHR | 5.22% | 3.23K | $702.8K |
| 2 | MODERNA | MRNA | 5.09% | 3.48K | $684.8K |
| 3 | GILEAD SCIENCES | GILD | 5.06% | 4.63K | $680.6K |
| 4 | ABBVIE | ABBV | 4.92% | 2.43K | $662.3K |
| 5 | THERMO FISHER SCIENTIFIC INC | TMO | 4.37% | 902 | $588.1K |
| 6 | BLK CSH FND TREASURY SL AGENCY | — | 4.16% | 560.00K | $560.0K |
| 7 | JOHNSON & JOHNSON | JNJ | 4.14% | 2.17K | $557.1K |
| 8 | IQVIA HOLDINGS INC | IQV | 3.70% | 1.92K | $497.8K |
| 9 | WATERS CORP | WAT | 3.67% | 1.15K | $493.5K |
| 10 | BIOGEN | BIIB | 3.49% | 2.15K | $469.6K |
| 11 | METTLER TOLEDO | MTD | 3.46% | 304 | $465.0K |
| 12 | VERTEX PHARMACEUTICALS | VRTX | 3.31% | 884 | $444.9K |
| 13 | MERCK & CO INC | MRK | 3.11% | 2.94K | $419.0K |
| 14 | EDWARDS LIFESCIENCES | EW | 2.97% | 4.74K | $399.0K |
| 15 | ROCHE PS PAR AG | ROP.SW | 2.69% | 853 | $361.2K |
| 16 | DEXCOM INC | DXCM | 2.44% | 3.88K | $327.6K |
| 17 | AMGEN INC | AMGN | 2.43% | 802 | $326.8K |
| 18 | ILLUMINA INC | ILMN | 2.29% | 1.16K | $308.0K |
| 19 | HALOZYME THERAPEUTICS | HALO | 2.07% | 2.53K | $278.0K |
| 20 | GENMAB SPONSORED ADR | GMAB | 1.94% | 7.23K | $260.7K |
| 21 | NOVARTIS AG | NOVN.SW | 1.84% | 1.75K | $247.9K |
| 22 | ARGENX SE ADR | ARGX | 1.69% | 277 | $226.8K |
| 23 | CHARLES RIVER LABORATORIES INTERNA | CRL | 1.53% | 689 | $205.3K |
| 24 | PFIZER | PFE | 1.52% | 7.36K | $204.7K |
| 25 | WUXI BIOLOGICS CAYMAN | 2269.HK | 1.49% | 29.00K | $199.9K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.24% | Paid (last 12 months) | $0.0812 |
| Frequency | Irregular | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Jun 15, 2026 | Last payment | $0.0812 (Jun 18, 2026) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 15, 2026 | Jun 15, 2026 | Jun 18, 2026 | $0.0812 |
| Dec 20, 2023 | Dec 21, 2023 | Dec 27, 2023 | $0.0072 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 17.43% / 16.83% | Sharpe 1Y / 3Y | 1.36 / 0.815 |
| Max drawdown 1Y / 3Y | -14.88% / -20.10% | Sortino 1Y | 2.25 |
| Beta vs S&P 500 (3Y) | 0.672 | Correlation vs S&P 500 (1Y) | 0.413 |
| Downside deviation 1Y | 10.56% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 12, 2026. Formulas →
Liquidity
| Volume today | 1.60K | Average volume | 1.99K |
| AUM | $13.7M | Premium/Discount | -2.01% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $0.00 | 0.00% | $13.7M → $13.7M |
| 1 Month | $73.9K | +0.56% | $13.1M → $13.7M |
| 1 Week | $241.9K | +1.79% | $13.5M → $13.7M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for BMED
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.